Revolutionizing therapeutics: Exploring novel biotechnological methods for disease management and treatment
The investigation of the ever-changing field of therapeutics dives deeply into cutting-edge biotechnological techniques, with a particular emphasis on the management and treatment of disease. The amalgamation of state-of-the-art biotechnological methodologies presents unequaled prospects to transform healthcare methodologies. Gene editing technologies, targeted drug delivery systems, immunotherapies, and regenerative medicine procedures are among the range of novel approaches In order to maximize therapeutic outcomes, the research also explores the potential of precision medicine and personalized medicine, concentrating on patient-specific therapy modalities, biomarker identification, and genomic insights. Precision medicine is a paradigm change towards tailored treatments that consider the specific genetic composition of each patient, the progression of their condition, and the efficacy of their treatment or treating a broad range of illnesses, including infectious infections, chronic ailments, and genetic problems. The ethical and safe implementation of these novel medicines is emphasized by patient-centered approaches, regulatory frameworks, and ethical considerations. Insights into new developments and potential paths in biotechnology treatments are offered by this study. With cutting-edge cell-based medicines and inventive gene therapies, patients and medical professionals can now look forward to a brighter future. As a whole, this investigation shows how biotechnology can fundamentally alter how diseases are managed and treated, providing a solid basis for further study and practical applications.
Authors
- Prerna Mehta (ORCID: https://orcid.org/0009-0003-1300-588X)
Institutions
- Indian Institute of Technology Bhilai (IN)
Publication Details
- Published
- 2025-06-07
- DOI
- https://doi.org/10.52679/bi.e202531004
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.00